# JAZZ catalysts: Jazz Pharmaceuticals plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/jazz/catalysts

> Jazz Pharmaceuticals plc (JAZZ) has 25 upcoming catalysts. The next is the Ziihera® (zanidatamab) topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Jazz Pharmaceuticals plc |
| Ticker | JAZZ (Nasdaq) |
| SEC CIK | 1232524 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/jazz |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 15, 2020 | [Zepzelca (lurbinectedin) FDA approval](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ |  | completed, approved | "NDA213702 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200615, review_priority PRIORITY; sponsor_name JAZZ; product ZEPZELCA (LURBINECTEDIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213702%22)) |
| July 21, 2020 | [Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) FDA approval](https://sec-api.dev/pdufa/oxybate-oxybate-oxybate-oxybate) | JAZZ |  | completed, approved | "NDA212690 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20200721, review_priority PRIORITY; sponsor_name JAZZ; product XYWAV (CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212690%22)) |
| August 12, 2021 | [Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate) label expansion decision](https://sec-api.dev/pdufa/oxybate-oxybate-oxybate-oxybate) | JAZZ |  | completed, approved | "NDA212690 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210812, review_priority PRIORITY; sponsor_name JAZZ; product XYWAV (CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212690%22)) |
| Nov 2022 | [Suvecaltamide trial start](https://sec-api.dev/pdufa/suvecaltamide) | JAZZ | Parkinson's disease tremor | completed | "Additionally, in November 2022, we initiated a Phase 2 trial of suvecaltamide in patients with Parkinson's disease tremor." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000011/jazz-20241231.htm)) |
| Oct 2024 | [Jazz Pharmaceuticals plc topline data readout](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed, met | "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)) |
| Oct 2024 | [Tecentriq® (atezolizumab) topline data readout](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | completed, met | "In October 2024, we announced positive top-line results from the Phase 3 IMforte trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm)) |
| Oct 2024 | [Zepzelca (lurbinectedin) topline data readout](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ |  | completed, met | "In October 2024, we announced positive top-line results from the trial showing a statistically significant and clinically meaningful progression-free survival and overall survival benefit for Zepzelca and atezolizumab in combination in the first-line maintenance setting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000074/jazz-20250930.htm)) |
| November 20, 2024 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with previously treated, unresectable or metastatic HER2-positive | completed, approved | "On November 20, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") accelerated approval of Ziihera®(zanidatamab-hrii) 50mg/mL for injection for IV for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312524262940/d832756d8k.htm)) |
| 1H 2025 | [GEA-01 NDA/BLA submission](https://sec-api.dev/pdufa/gea-01) | JAZZ |  | scheduled | ""We are pleased with the continued progress of our late-stage pipeline assets, including the recent launch of Ziihera in 2L HER2+ (IHC3+) BTC, upcoming top-line data readout from the HERIZON-GEA-01 trial in 1L GEA, which we now expect in the second half of 2025, and highly encouraging results from the Phase 3 IMforte trial, which we expect to submit as part of an sNDA for Zepzelca® in 1L ES-SCLC in the first half of 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm)) |
| 2025 | [JZP441 trial start](https://sec-api.dev/pdufa/jzp441) | JAZZ |  | scheduled | "Following additional review of the trial findings and input from FDA, we plan to initiate a small Phase 1b trial of JZP441 in narcolepsy Type 1 patients in 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000011/jazz-20241231.htm)) |
| 1H 2025 | [Zepzelca (lurbinectedin) NDA/BLA submission](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ |  | scheduled | "EmpowHER late-line BC trial is enrolling approach to capital Meaningful growth opportunity in IH allocation Zepzelca Treatment of choice in 2L SCLC Expect to submit sNDA for 1L ES-SCLC in 1H25 Near universal adoption in U.S. pediatric protocols" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/d699726dex991.htm)) |
| 1H 2025 | [Tecentriq® (atezolizumab) NDA/BLA submission](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | scheduled | "•On track to submit an sNDA in 1H25 for Zepzelca in combination with Tecentriq® (atezolizumab) as maintenance therapy in 1L ES-SCLC based on the potentially practice-changing results from the Phase 3 IMforte trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm)) |
| February 25, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm)) |
| February 25, 2025 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with previously treated, unresectable or metastatic HER2-positive | completed, approved | "•In 4Q24, announced U.S. FDA granted accelerated approval of Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000009/a4q24financialpr.htm)) |
| May 6, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/a1q25financialpr.htm)) |
| Jun 2025 | [Tecentriq® (atezolizumab) label expansion decision](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | completed, approved | "In June 2025, FDA granted priority review of the sNDA and we subsequently received FDA approval in October 2025 for the combination as a first-line maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000025/jazz-20260331.htm)) |
| Aug 2025 | [Modeyso (dordaviprone) FDA approval](https://sec-api.dev/pdufa/dordaviprone) | JAZZ |  | completed, approved | "•Modeyso received accelerated approval from the FDA ahead of its PDUFA date; initiated commercial launch in August 2025 with strong initial uptake and sales of $11.0 million in 3Q25." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm)) |
| August 5, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm)) |
| August 18, 2025 | [Modeyso (dordaviprone) PDUFA date](https://sec-api.dev/pdufa/dordaviprone) | JAZZ |  | scheduled | "Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871dex991.htm)) |
| August 30, 2025 | [Zw25 (zanidatamab) primary completion](https://sec-api.dev/pdufa/zw25-zanidatamab) | JAZZ |  | completed | "NCT03929666 (A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-30 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03929666)) |
| Oct 2025 | [Tecentriq® (atezolizumab) FDA approval](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | completed, approved | "In October 2025, we received FDA approval for the combination as a maintenance treatment of adult patients with extensive-stage SCLC whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)) |
| Q4 2025 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | scheduled | "•Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm)) |
| Q4 2025 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | JAZZ |  | scheduled | "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continue to advance our development programs and execute our long-term growth strategy, said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. With recent progress in regulatory approvals for zanidatamab in key international markets, including the U.S., Europe, and China, a much-anticipated, upcoming topline data readout for HERIZON-GEA-01 in the fourth quarter of 2025, and continued progress across our novel, wholly-owned pipeline, we believe Zymeworks is entering a significant period of opportunity for value creation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000119312525177505/d86037dex991.htm)) |
| October 2, 2025 | [Zepzelca (lurbinectedin) label expansion decision](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ |  | completed, approved | "NDA213702 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority PRIORITY; sponsor_name JAZZ; product ZEPZELCA (LURBINECTEDIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213702%22)) |
| October 7, 2025 | [Tecentriq® (atezolizumab) PDUFA date](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | scheduled | "•Zepzelca and atezolizumab (Tecentriq®) combination granted U.S. FDA Priority Review for 1L maintenance treatment of ES-SCLC based on positive data from IMforte trial; PDUFA action date of October 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm)) |
| Nov 2025 | [Epidiolex® (cannabidiol) trial start](https://sec-api.dev/pdufa/cannabidiol) | JAZZ |  | completed | "In November 2025, we initiated a Phase 1b trial evaluating cannabidiol oral solution as an adjunctive treatment in reducing the frequency of focal seizures compared to the baseline as well as the effect of it on health outcome endpoints in early line and refractory participants with focal-onset seizures." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm)) |
| November 5, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000073/a3q25financialpr.htm)) |
| November 17, 2025 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | JAZZ | HER2-positive locally advanced or metastatic GEA | completed, positive | "On November 17, 2025, we announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA"), including cancers of the stomach, gastroesophageal junction, and esophagus." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm)) |
| November 17, 2025 | [Jazz Pharmaceuticals plc topline data readout](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed, positive | "November 17, 2025 — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm)) |
| Jan 2026 | [Generic NDA/BLA submission](https://sec-api.dev/pdufa/generic) | JAZZ |  | completed | "Furthermore, in January 2026, we received notices from Tris Pharma that it had filed with FDA a Section 505(b)(2) NDA for generic versions of Xyrem and Xywav." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm)) |
| Q1 2026 | [Ziihera® (zanidatamab) NDA/BLA submission](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | first-line HER2+ locally advanced or metastatic GEA | scheduled | "Based on these data, our partner Jazz expects to complete the supplemental Biologics License Application submission for zanidatamab in the first quarter of 2026 for the treatment of first-line HER2+ locally advanced or metastatic GEA under the real-time oncology review program in the U.S., where zanidatamab has been granted Breakthrough Therapy Designation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/ex991q42025_earningsxrelea.htm)) |
| 1H 2026 | [TEVIMBRA® (tislelizumab) NDA/BLA submission](https://sec-api.dev/pdufa/tislelizumab) | JAZZ |  | scheduled | "We plan to quickly engage FDA and expect to submit a supplemental Biologics License Application (sBLA) in the U.S. in first half of 2026 to support Ziihera as a first-line treatment for patients with HER2+ locally advanced or metastatic GEA for use as part of a standard chemotherapy regimen with and without tislelizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm)) |
| 1H 2026 | [GEA-01 NDA/BLA submission](https://sec-api.dev/pdufa/gea-01) | JAZZ |  | scheduled | "This press release contains forward-looking statements, including, but not limited to, statements related to Ziihera's potential as a new standard of care in HER2+ first-line GEA and other HER2-expressing cancers, expected timing of OS data from the pivotal Phase 3 HERIZON-GEA-01, plans to submit a sBLA in first half of 2026 and other statements that are not historical facts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm)) |
| February 24, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/a4q25financialpr.htm)) |
| Apr 2026 | [Ziihera® (zanidatamab) NDA/BLA acceptance](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | completed | "•In April 2026, FDA accepted the zanidatamab sBLA in GEA for a Priority Review, with a PDUFA date of August 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm)) |
| mid-2026 | [Ziihera® (zanidatamab) interim data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | scheduled | "The trial is ongoing with an additional planned OS interim analysis for Ziihera plus chemotherapy currently expected in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525283887/d827060dex991.htm)) |
| May 5, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm)) |
| Jun 2026 | [Topotecan topline data readout](https://sec-api.dev/pdufa/topotecan) | JAZZ |  | completed, missed | "In June 2026, we announced top-line results from the LAGOON trial, which did not meet its primary OS endpoint evaluating Zepzelca as monotherapy or in combination with irinotecan compared with investigators' choice of topotecan or irinotecan." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)) |
| Q3 2026 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | JAZZ |  | scheduled | "•The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/ex991q22026_earningsxrelea.htm)) |
| July 15, 2026 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | completed | "NCT05152147 (A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05152147)) |
| August 3, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| August 25, 2026 | [Ziihera® (zanidatamab) PDUFA date](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | with first-line | completed, approved | "•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| August 25, 2026 | [Jazz Pharmaceuticals plc PDUFA date](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | scheduled | "Our sBLA based on these results is currently under Priority Review with FDA and has a PDUFA date of August 25, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)) |
| August 25, 2026 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | completed, approved | "DUBLIN, August 25, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm)) |
| late 2026 | [Jazz Pharmaceuticals plc topline data readout](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | scheduled | "•Phase 3 ACTION trial remains on track with top-line readout expected late 2026 / early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm)) |
| Sep 2026 | [JZP269 trial start](https://sec-api.dev/pdufa/jzp269) | JAZZ |  | completed | "In September 2026, we received IND clearance for JZP269, a differentiated orexin-2 receptor agonist, and initiated a Phase 1 first-in-human trial to evaluate the safety, tolerability and wake-promoting effects of JZP269 in sleep-deprived healthy participants." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000057/jazz-20260930.htm)) |
| September 30, 2026 | [Tecentriq® (atezolizumab) FDA approval](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | completed, approved | "•On September 30, 2026, the FDA approved the label supplement removing the second-line indication." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| November 2, 2026 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| November 4, 2026 | [Zw25 (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zw25-zanidatamab) | JAZZ |  | completed | "NCT03929666 (A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-30 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03929666?tab=results)) |
| Dec 2026 to Mar 2027 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Breast Cancer; Gastric Cancer; Esophageal Cancer | scheduled | "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06695845)) |
| December 2026 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Breast Cancer; Gastric Cancer; Esophageal Cancer | scheduled | "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06695845)) |
| 1H 2027 | [Ziihera® (zanidatamab) interim data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ |  | scheduled | "•Anticipate the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on current pace of event accrual." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)) |
| April 16, 2027 | [Epidiolex® (cannabidiol) PDUFA date](https://sec-api.dev/pdufa/cannabidiol) | JAZZ |  | scheduled | "•The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000056/a3q26earningsrelease.htm)) |
| late 2027 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | JAZZ |  | scheduled | "•EmpowHER-BC-303 trial in mBC patients previously treated with, or intolerant to, trastuzumab deruxtecan on track to complete enrollment in 1H27, with top-line results expected in late 2027 or early 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/a4q25financialpr.htm)) |
| Dec 2027 to Mar 2028 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | HER2-positive Breast Cancer; Breast Cancer | scheduled | "NCT07102381 (A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-29 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102381)) |
| Dec 2027 to Mar 2028 | [Xywav topline data readout](https://sec-api.dev/pdufa/xywav) | JAZZ | Narcolepsy; Idiopathic Hypersomnia | scheduled | "NCT07625280 (A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-23 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07625280)) |
| December 2027 | [Xywav primary completion](https://sec-api.dev/pdufa/xywav) | JAZZ | Narcolepsy; Idiopathic Hypersomnia | scheduled | "NCT07625280 (A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-23 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07625280)) |
| December 2027 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | HER2-positive Breast Cancer; Breast Cancer | scheduled | "NCT07102381 (A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-29 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102381)) |
| Apr to Jul 2028 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Metastatic HER2-positive Breast Cancer | scheduled | "NCT06435429 (A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-28 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435429)) |
| April 2028 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Metastatic HER2-positive Breast Cancer | scheduled | "NCT06435429 (A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-28 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435429)) |
| June 2028 | [Dordaviprone (onc201) primary completion](https://sec-api.dev/pdufa/dordaviprone-onc201) | JAZZ | H3 K27M; Glioma | scheduled | "NCT05580562 (ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05580562)) |
| Jun to Sep 2028 | [Dordaviprone (onc201) topline data readout](https://sec-api.dev/pdufa/dordaviprone-onc201) | JAZZ | H3 K27M; Glioma | scheduled | "NCT05580562 (ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05580562)) |
| August 2028 | [Jzp926 capsule primary completion](https://sec-api.dev/pdufa/jzp926) | JAZZ | Juvenile Myoclonic Epilepsy | scheduled | "NCT07723963 (A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723963)) |
| Aug to Nov 2028 | [Jzp926 capsule topline data readout](https://sec-api.dev/pdufa/jzp926) | JAZZ | Juvenile Myoclonic Epilepsy | scheduled | "NCT07723963 (A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723963)) |
| Oct 2028 to Jan 2029 | [JZP3507 topline data readout](https://sec-api.dev/pdufa/jzp3507) | JAZZ | Meningioma | scheduled | "NCT07533942 (A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-25 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533942)) |
| October 2028 | [JZP3507 primary completion](https://sec-api.dev/pdufa/jzp3507) | JAZZ | Meningioma | scheduled | "NCT07533942 (A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-25 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533942)) |
| December 2028 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Biliary Tract Cancer | scheduled | "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282575)) |
| Dec 2028 to Mar 2029 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Biliary Tract Cancer | scheduled | "NCT06282575 (Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-01 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06282575)) |
| Dec 2028 to Mar 2029 | [ONC206 topline data readout](https://sec-api.dev/pdufa/onc206) | JAZZ | Advanced Pheochromocytoma and Paraganglioma; PCPG | scheduled | "NCT07282587 (Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282587)) |
| December 2028 | [ONC206 primary completion](https://sec-api.dev/pdufa/onc206) | JAZZ | Advanced Pheochromocytoma and Paraganglioma; PCPG | scheduled | "NCT07282587 (Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07282587)) |
| Aug to Nov 2029 | [Zepzelca (lurbinectedin) topline data readout](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459634)) |
| August 2029 | [Zepzelca (lurbinectedin) primary completion](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ | Extensive-stage Small-cell Lung Cancer | scheduled | "NCT07459634 (A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07459634)) |
| Sep to Dec 2029 | [Cbd-os topline data readout](https://sec-api.dev/pdufa/cbd-os) | JAZZ | Developmental and Epileptic Encephalopathy (DEE) | scheduled | "NCT07723976 (A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723976)) |
| September 2029 | [Cbd-os primary completion](https://sec-api.dev/pdufa/cbd-os) | JAZZ | Developmental and Epileptic Encephalopathy (DEE) | scheduled | "NCT07723976 (A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-04 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07723976)) |

## Drugs

- [Epidiolex® (cannabidiol)](https://sec-api.dev/pdufa/cannabidiol): 
- [Cbd-os](https://sec-api.dev/pdufa/cbd-os): Developmental and Epileptic Encephalopathy (DEE)
- [Modeyso (dordaviprone)](https://sec-api.dev/pdufa/dordaviprone): 
- [Dordaviprone (onc201)](https://sec-api.dev/pdufa/dordaviprone-onc201): H3 K27M
- [GEA-01](https://sec-api.dev/pdufa/gea-01): her2-positive locally advanced or metastatic gea
- [JZP269](https://sec-api.dev/pdufa/jzp269): 
- [JZP3507](https://sec-api.dev/pdufa/jzp3507): Meningioma
- [JZP441](https://sec-api.dev/pdufa/jzp441): 
- [Jzp926 capsule](https://sec-api.dev/pdufa/jzp926): Juvenile Myoclonic Epilepsy
- [Zepzelca (lurbinectedin)](https://sec-api.dev/pdufa/lurbinectedin): Extensive-stage Small-cell Lung Cancer
- [ONC206](https://sec-api.dev/pdufa/onc206): Advanced Pheochromocytoma and Paraganglioma
- [Xywav (calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate)](https://sec-api.dev/pdufa/oxybate-oxybate-oxybate-oxybate): 
- [Suvecaltamide](https://sec-api.dev/pdufa/suvecaltamide): parkinson's disease tremor
- [Topotecan](https://sec-api.dev/pdufa/topotecan): 
- [Xywav](https://sec-api.dev/pdufa/xywav): Narcolepsy
- [Ziihera® (zanidatamab)](https://sec-api.dev/pdufa/zanidatamab): with previously treated, unresectable or metastatic her2-positive, with 1l her2+ locally advanced or metastatic gea, with first-line, first-line her2+ locally advanced or metastatic gea, with previously treated, unresectable or metastatic her2+, with previously-treated, unresectable or metastatic her2-positive, Gastric Neoplasms, Biliary Tract Cancer
- [Zw25 (zanidatamab)](https://sec-api.dev/pdufa/zw25-zanidatamab): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/jazz/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JAZZ catalysts: Jazz Pharmaceuticals plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/jazz/catalysts

```bibtex
@misc{secapidev_companies_jazz_catalysts_20261116,
  title        = {JAZZ catalysts: Jazz Pharmaceuticals plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/jazz/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_jazz_catalysts_20261116","title":"JAZZ catalysts: Jazz Pharmaceuticals plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/jazz/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
